Stock Analiz

Prokidney Corp. PROK

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$1.04Market cap $417M
Open the interactive analysis →

Prokidney Corp. (PROK) is a healthcare company listed in the US with a market value of about $417M. In the twelve months to September 30, 2026 it had revenue of $775000 and net income of -$103M, a net margin of -13326.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -155%.

About Prokidney

Prokidney is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 549% over three years (dilution for shareholders). It spends 12780% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S538.3
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-40.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1075.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-44116.5%
ROIC (5-yr avg.)-154.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$775000$893000$76000$0$0——
Net income-$103M-$69M-$61M-$35M-$148M-$55M-$27M
Free cash flow-$168M-$135M-$156M-$124M-$79M-$55M-$31M
EPS (diluted)$-0.26$-0.17——$-0.23——
Net margin-13326.7%-7725.2%-80507.9%————
ROIC—————-154.7%-271.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $6.50, 522% above the current price; targets range from $1.00 to $12.00; the consensus rating is “Buy”; expected EPS is $-0.65 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Prokidney pay a dividend?

Not currently.

Is Prokidney a good stock to buy?

We do not give buy or sell advice. Prokidney scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.